- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02286934
Cytochrome P450 2D6 Genotype on the Clinical Effect of Carvedilol
A Clinical Trial to Investigate the Influence of Cytochrome P450 2D6 Polymorphism on the Pharmacokinetic/Pharmacodynamics Characteristics of Carvedilol in Healthy Korean Volunteers
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study has an open-label, one-sequence, multiple drug administration design. The purpose of this study is as follows;
To evaluate the change of the result of Isoproterenol Sensitivity Test according to Cytochrome P450 2D6 genotype after the multiple administration of carvedilol
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Gyounggi
-
Seongnam, Gyounggi, Korea, Republic of
- Seoul National University Bundang Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy Subjects aged 20 - 45 years
- A body mass index (BMI) in the range 18.0 kg/m2 (inclusive) - 27.0 kg/m2 (inclusive).
- Sufficient ability to understand the nature of the study and any hazards of participating in it. Provide written informed consent after being fully. informed about the study procedures.
Exclusion Criteria:
- Presence or history of hypersensitivity or allergic reactions to drugs including investigational product (Carvedilol, Isoproterenol).
- Subject judged not eligible for study participation by investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Carvedilol
Isoproterenol Sensitivity Test
Measure change of heart rates after 1, 2, 3 minutes post injection of isoproterenol. |
Day 0, 1, 8 : Isoproterenol Sensitivity Test
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
AUC (area under the plasma concentration-time curve) of carvedilol
Time Frame: predose and 0.25, 0.5, 1, 2, 3, 4, 6, 12, 24h postdose
|
predose and 0.25, 0.5, 1, 2, 3, 4, 6, 12, 24h postdose
|
Cmax (Maximum plasma concentration) of carvedilol
Time Frame: predose and 0.25, 0.5, 1, 2, 3, 4, 6, 12, 24h postdose
|
predose and 0.25, 0.5, 1, 2, 3, 4, 6, 12, 24h postdose
|
Collaborators and Investigators
Investigators
- Principal Investigator: Jae-Yong Chung, MD, PhD, Department of Clinical Pharmacology and Therapeutics, Seoul National University Bundang Hospital, Seongnam, Kore
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Adrenergic beta-Antagonists
- Adrenergic Antagonists
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Vasodilator Agents
- Autonomic Agents
- Peripheral Nervous System Agents
- Protective Agents
- Adrenergic Agonists
- Cardiotonic Agents
- Membrane Transport Modulators
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Calcium-Regulating Hormones and Agents
- Calcium Channel Blockers
- Antioxidants
- Adrenergic beta-Agonists
- Sympathomimetics
- Adrenergic alpha-1 Receptor Antagonists
- Adrenergic alpha-Antagonists
- Carvedilol
- Isoproterenol
Other Study ID Numbers
- CYP-CVDL-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Carvedilol
-
Chong Kun Dang PharmaceuticalCompletedHypertensionKorea, Republic of
-
Zunyi Medical CollegeUnknownChronic AppendicitisChina
-
E-DA HospitalTerminatedVariceal BleedingTaiwan
-
GlaxoSmithKlineCompletedMetabolic, CardiovascularUnited Kingdom
-
Andhra Medical CollegeCompleted
-
Institute of Liver and Biliary Sciences, IndiaRecruiting
-
Owen Chan, PhDTerminated
-
CTI-1, LLCGlaxoSmithKline; CTI Clinical Trial and Consulting ServicesCompletedCongestive Heart FailureUnited States
-
University of MinnesotaGlaxoSmithKlineCompletedPre-hypertensionUnited States
-
GlaxoSmithKlineCompletedHeart Failure, CongestiveJapan